[go: up one dir, main page]

FI20000720L - Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi - Google Patents

Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi Download PDF

Info

Publication number
FI20000720L
FI20000720L FI20000720A FI20000720A FI20000720L FI 20000720 L FI20000720 L FI 20000720L FI 20000720 A FI20000720 A FI 20000720A FI 20000720 A FI20000720 A FI 20000720A FI 20000720 L FI20000720 L FI 20000720L
Authority
FI
Finland
Prior art keywords
parkinson
disease
extended
treatment
release tablet
Prior art date
Application number
FI20000720A
Other languages
English (en)
Swedish (sv)
Other versions
FI20000720A7 (fi
Inventor
Robert Tzu-Chi Ju
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI20000720L publication Critical patent/FI20000720L/fi
Publication of FI20000720A7 publication Critical patent/FI20000720A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI20000720A 1997-09-30 2000-03-29 Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi FI20000720A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
PCT/US1998/017992 WO1999016442A2 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Publications (2)

Publication Number Publication Date
FI20000720L true FI20000720L (fi) 2000-03-29
FI20000720A7 FI20000720A7 (fi) 2000-03-29

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20000720A FI20000720A7 (fi) 1997-09-30 2000-03-29 Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi

Country Status (22)

Country Link
US (2) US6197339B1 (fi)
EP (1) EP1017391B1 (fi)
JP (1) JP2001517701A (fi)
KR (1) KR100516095B1 (fi)
CN (1) CN1195518C (fi)
AT (1) ATE297208T1 (fi)
AU (1) AU742941B2 (fi)
BR (1) BR9812687A (fi)
CA (1) CA2301869A1 (fi)
DE (1) DE69830503T2 (fi)
DK (1) DK1017391T3 (fi)
ES (1) ES2242296T3 (fi)
FI (1) FI20000720A7 (fi)
HU (1) HUP0004586A2 (fi)
NO (1) NO320303B1 (fi)
NZ (1) NZ504221A (fi)
PL (1) PL191125B1 (fi)
PT (1) PT1017391E (fi)
RU (1) RU2205007C2 (fi)
SI (1) SI1017391T1 (fi)
SK (1) SK3612000A3 (fi)
WO (1) WO1999016442A2 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1149100A1 (en) 1999-02-05 2001-10-31 PHARMACIA & UPJOHN COMPANY PROCESS TO PREPARE (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO 4,5,1-ij]-QUINOLIN-2(1H)-ONE
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
AU2002360600B2 (en) * 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
JP2006506360A (ja) * 2002-10-04 2006-02-23 ファルマシア・コーポレーション パーキンソン病の治療のための医薬組成物
MXPA05003512A (es) * 2002-10-04 2005-06-03 Pharmacia Corp Composiciones y metodos para el tratamiento de la disfuncion sexual.
JP2006505580A (ja) * 2002-10-25 2006-02-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 複素環アミン型化合物の神経保護剤としての使用
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
MXPA05008033A (es) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Composiciones de milnacipran en forma de multiparticulas para administracion oral.
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
ES2355735T5 (es) * 2004-08-13 2014-06-27 Boehringer Ingelheim International Gmbh Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso
EP2431026A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
RU2014114119A (ru) 2011-09-23 2015-10-27 Рош Гликарт Аг Биспецифические анти-egfr/анти igf-1r-антитела
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CA3232088A1 (en) * 2021-09-17 2023-03-23 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
DE69016430T2 (de) * 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DK1017391T3 (da) 2005-08-22
KR100516095B1 (ko) 2005-09-23
CN1195518C (zh) 2005-04-06
HK1030163A1 (en) 2001-04-27
ATE297208T1 (de) 2005-06-15
WO1999016442A2 (en) 1999-04-08
JP2001517701A (ja) 2001-10-09
NO20001624L (no) 2000-03-29
US6197339B1 (en) 2001-03-06
RU2205007C2 (ru) 2003-05-27
NZ504221A (en) 2004-11-26
BR9812687A (pt) 2000-08-22
DE69830503D1 (de) 2005-07-14
EP1017391A2 (en) 2000-07-12
AU742941B2 (en) 2002-01-17
EP1017391B1 (en) 2005-06-08
PL339946A1 (en) 2001-01-15
ES2242296T3 (es) 2005-11-01
US20010053386A1 (en) 2001-12-20
SK3612000A3 (en) 2000-09-12
CA2301869A1 (en) 1999-04-08
WO1999016442A3 (en) 1999-06-17
HUP0004586A2 (hu) 2001-06-28
DE69830503T2 (de) 2006-03-16
CN1268890A (zh) 2000-10-04
PL191125B1 (pl) 2006-03-31
AU9296498A (en) 1999-04-23
PT1017391E (pt) 2005-09-30
KR20010030776A (ko) 2001-04-16
FI20000720A7 (fi) 2000-03-29
NO20001624D0 (no) 2000-03-29
SI1017391T1 (sl) 2005-12-31
NO320303B1 (no) 2005-11-21

Similar Documents

Publication Publication Date Title
FI20000720L (fi) Pitkitettyyn vapautumiseen perustuva tablettiformulaatio Parkisonin taudin hoitamiseksi
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
EE9900469A (et) Sulfoonamiidid endoteliini vahendatud haiguste raviks
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
EE200300214A (et) Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
EP0331620A3 (en) Agent for the treatment of parkinson's disease
AP2001002102A0 (en) Pharmaceutical agents for the treatment of parkinson's disease and adhd and microadenomas
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
IL119417A0 (en) Drug for Parkinson's disease
BR9711225A (pt) Composi-{es de propentofilina transd-rmica para o tratamento do mal de alzheimer
ZA963935B (en) The use of glyceryl triacetate for treatment of onychomycoses
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
NO982562D0 (no) Sammensetning for behandling av smerte
FI952953L (fi) Aineita metabolisten luustosairauksien hoitamiseen
ID28817A (id) Penggunaan turunan-turunan tetrahidropiridin (atau4-hidropiperidin)-butilazol dalam pembuatan obat untuk perawatan nyeri
HUP9800272A3 (en) Use of penciclovir for the treatment of human herpes-virus-8
HUP0000570A3 (en) Use of 17 alpha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states
ZA986324B (en) Composition for the treatment of immunodeficiency disease
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease
HUP0000476A3 (en) Use of 17 betha-dihydroequilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states